PUBT 
I'm LongbridgeAI, I can summarize articles.
- Radiopharm Theranostics entered a partnership with Siemens Healthineers to manufacture, distribute 18F-labeled RAD101 doses for a U.S. Phase 3 trial. * Supply support targets a planned registrational study for RAD101, an F-18 PET imaging agent for suspected recurrent brain metastases post-radiotherapy. * Collaboration comes ahead of an FDA End-of-Phase 2 meeting set for Oct. 1, 2026 to align Phase 3 design. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608170730PRIMZONEFULLFEED1001257938) on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)
